Peter Sayre

MD PhD

Hematologist-oncologist

Dr. Peter Sayre specializes in adult bone marrow transplantation and other treatments for leukemia, multiple myeloma, lymphoma and Hodgkin's disease.

Sayre is a director of clinical research at UCSF. His research interests focus on allogeneic stem cell transplants (which use cells from a matching donor) and leukemia in older adults. His work on these subjects has been widely published in medical and other scientific journals.

Sayre earned an undergraduate degree in philosophy from Yale College, graduating magna cum laude. He earned his medical degree at the Rutgers Robert Wood Johnson Medical School, and he earned a doctorate in immunology at Harvard University. He completed a fellowship in hematology and oncology at UCSF before joining the faculty in 1996.

  • Education

    Robert Wood Johnson Medical School, 1990

  • Residencies

    UC San Diego, Internal Medicine, 1993

  • Fellowships

    UCSF, Oncology, 1996

    UCSF, Hematology, 1996

  • Board Certifications

    Hematology, American Board of Internal Medicine

  • Academic Title

    Professor

  • Languages

    French

    Spanish

Conditions I specialize in

Treatments I provide

Clinics I work with

View map

Cancer Immunotherapy Clinic

Bakar Precision Cancer Medicine Building

1825 Fourth St., Fifth Floor
San Francisco, CA 94158

(415) 353-2421

Hematology and Blood and Marrow Transplant

400 Parnassus Ave., Fourth Floor
San Francisco, CA 94143

(415) 353-2421
M-F, 8 a.m. - 5 p.m

My reviews

4.8

Overall Experience
40 Reviews
Explained things in a way that was easy to understand
38 Reviews
Did the doctor pay attention to your concerns
40 Reviews
Gave easy to understand instructions about taking care of health problems or concerns
38 Reviews
Knew the important information about your medical history
40 Reviews
The provider showed respect for what you had to say
40 Reviews
The provider spent enough time with me
40 Reviews
Read all reviews About our process

Selected research

Decorative Caduceus

Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (A...

Proportion of patients achieving a best response of CR (morphologic CR [mCR], cytogenetic CR [CRc], molecular CR [CRm], or CRh per Interworking Group AML response criteria.

Recruiting

Contact me

Providers on my team

Share